Dr. Scott Gottlieb was appointed the new commissioner of the Food and Drug Administration (FDA) on May 11, 2017. He is a physician and a cancer survivor, having been successfully treated for Hodgkin’s lymphoma. Gottlieb has previously commented that the...
ARC held its biannual Industry Advisory Council meeting in Boston on March 27th, 2017. The day-long meeting was attended by representatives from pharmaceutical and biotech companies developing new treatments for amyloidosis. This provided a unique opportunity for these companies...
Rare disease day is on February 28th. The entire week provides a unique opportunity to raise awareness of key policy issues that affect amyloidosis. Patient organizations, NIH and other government entities, medical researchers, and pharmaceutical companies developing treatments for rare...
On December 13th, President Obama signed into law the 21st Century Cures Act, a game-changing bill for medical innovation. We are very grateful to Representatives Fred Upton (R-MI) and Diana DeGette (D-CO), as well as members of their staff, for...
ARC Submits Guidance on Drug Development in AL Amyloidosis to FDA
The Amyloidosis Research Consortium (ARC) submitted a draft guidance for industry on developing drugs for AL amyloidosis to the Food and Drug Administration (FDA), to improve the design of clinical trials and accelerate the review of potential therapies. Patients with...
Join our email list to stay up to date on the latest Amyloidosis news.
Dr. Sharmila Dorbala explained the role that medical imaging techniques play in both diagnosing and managing amyloidosis. We also explored the role of PYP scans, EKG, and Echocardiogram imaging as well as their interpretation and limitations.
Dr. Dorbala will also highlighted novel imaging techniques for amyloidosis that are currently being studied and the role these might play in the future.
Original Presentation Date:
April 30, 2024
0:00 — Introduction
2:02 — Start of presentation
3:14 — Amyloidosis overview
5:59 — How do we diagnosis amyloidosis?
15:23 — Echocardiography overview
16:14 — MRI overview
17:42 — SPECT/PET nuclear imaging overview
18:48 — What are we imaging in cardiac amyloidosis?
32:07 — How do we use imaging in clinical care?
42:45 — The future of amyloid imaging
44:52 — Using imaging to track treatment changes
49:35 — Start of Q&A session
49:42 — What are NYHA classes? How early can imaging be used to diagnose amyloidosis?
52:15 — What do longitudinal strain numbers indicate?
54:19 — What should I know about Dr. Jon Wall’s work at the University of Tennessee and Attralus?
56:15 — What level of amyloid showing in imaging tests requires treatment?
58:52 — Can imaging techniques identify amyloid in peripheral nerves?